Healthcare Industry News:  joint replacement 

Devices Dental

 News Release - March 8, 2007

Biomet Introduces NanoTite Dental Implant Technology

WARSAW, Ind.--(HSMN NewsFeed)--Biomet, Inc. (NASDAQ:BMET ) announced today that Biomet 3i, the Company's dental reconstructive device subsidiary, has introduced a new dental implant that utilizes nanotechnology. The NanoTite Implant builds upon the benefits of Biomet 3i's OSSEOTITE Implant by adding deposits of nano-scale calcium phosphate crystals to approximately 50% of the surface. According to pre-clinical studies, these nano-scale deposits create a complex surface on the implant that appears to play a key role in how the implant bonds with the bone. Human bone recognizes calcium phosphate as biologically natural, allowing the bone and implant to bond during healing.

Steven F. Schiess, President of Biomet 3i, commented, "The new NanoTite Implant represents a notable advancement in dental implant technology and we are pleased to announce its introduction to the market today."

Dental implants replace single or multiple missing teeth due to cavities, decay, trauma or disease and are designed to help preserve bone structure and natural facial contours. The 2007 dental reconstructive device market is estimated to be approximately $625 million in the United States and exceeds $2 billion worldwide, growing at an annual rate of 15-17%.

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.

Forward-Looking Statements

This press release contains certain statements that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are qualified by the inherent risks and uncertainties surrounding future expectations generally, and also may materially differ from actual future experience involving any one or more of such statements. Such risks and uncertainties include our ability to develop and market new products and technologies in a timely manner, the effect of the pending merger on Biomet's business and its relationship with customers, distributors, employees and suppliers and the risk factors as set forth from time to time in Biomet's filings with the SEC. The inclusion of a forward-looking statement herein should not be regarded as a representation by Biomet that Biomet's objectives will be achieved. Biomet undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.


Source: Biomet, Inc

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.